









Markets
/
Stocks
/
nasdaq-dyai
/

Dyadic International Inc

DYAI

0.852USD

+0.002+0.26%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

30.82MMarket Cap

LossP/E TTM



Dyadic International Inc

0.852

+0.002+0.26%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Dyadic International Inc

Currency: USD Updated: 2026-02-06

Key Insights

Dyadic International Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 144 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Dyadic International Inc's Score

Industry at a Glance

Industry Ranking

144 / 392

Overall Ranking

289 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Dyadic International Inc Highlights

StrengthsRisks

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 19.28% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 3.50M.

Overvalued

The company’s latest PE is -3.86, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 165.10K shares of this stock.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.000

Target Price

+724.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Dyadic International Inc is 7.35, ranking 118 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 1.16M, representing a year-over-year decrease of 40.50%, while its net profit experienced a year-over-year decrease of 871.20%.

Score

Industry at a Glance

Previous score

7.35

Change



Financials

6.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.70

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.52

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Dyadic International Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Dyadic International Inc is 6.15, ranking 324 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.86, which is -5.74% below the recent high of -3.64 and -156.03% above the recent low of -9.89.

Score

Industry at a Glance

Previous score

6.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 144/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Dyadic International Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 5.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Buy

Current Rating

7.000

Target Price

+724.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Dyadic International Inc

DYAI

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Dyadic International Inc is 5.82, ranking 292 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.94 and the support level at 0.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.88

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.005

Sell

RSI(14)

40.996

Neutral

STOCH(KDJ)(9,3,3)

39.218

Neutral

ATR(14)

0.044

Low Volatility

CCI(14)

-113.150

Sell

Williams %R

65.088

Sell

TRIX(12,20)

-0.322

Sell

StochRSI(14)

54.382

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.852

Sell

MA10

0.868

Sell

MA20

0.883

Sell

MA50

0.918

Sell

MA100

0.991

Sell

MA200

0.993

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Dyadic International Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 14.14%, representing a quarter-over-quarter decrease of 0.52%. The largest institutional shareholder is The Vanguard, holding a total of 914.96K shares, representing 2.53% of shares outstanding, with 6.57% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Emalfarb (Mark A)

4.73M

Francisco Trust

3.41M

Apis Capital Advisors LLC

1.54M

The Vanguard Group, Inc.

Star Investors

914.96K

+6.31%

Chapin Davis Asset Management

932.00K

+5.57%

Perkins Capital Management, Inc.

348.05K

+627.38%

Truist Bank

326.20K

+30.48%

Tarnok (Michael P)

281.03K

+3.99%

Geode Capital Management, L.L.C.

265.41K

+2.41%

BlackRock Institutional Trust Company, N.A.

251.37K

+0.62%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Dyadic International Inc is 2.05, ranking 257 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.